Intrathekales Cytarabin, Methotrexat und Hydrocortison zur Vorbeugung von hochgradigem chimärem Antigenrezeptor T-Zell-assoziiertes Neurotoxizitätssyndrom
Eine Phase-2
This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal [IT]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of IT chemotherapy in the prevention of high grade ICANS.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of IT chemotherapy in the prevention of any grade ICANS.
II. To evaluate safety of IT chemotherapy. III. To evaluate the effect of IT chemotherapy on corticosteroid use. IV. To evaluate the effect of IT chemotherapy on anakinra use.
EXPLORATORY OBJECTIVES:
I. To evaluate the effect of IT chemotherapy on time to ICANS onset. II. To evaluate the effect of IT chemotherapy on duration of ICANS. III. To evaluate the burden of treatment mediated serious adverse events (SAEs).
OUTLINE:
Patients receive cytarabine IT, methotrexate IT, and hydrocortisone IT over 3-5 minutes via lumbar puncture (LP) on day 4 post-standard of care (SOC) Axi-cel (Yescarta) or Brexu-cel (Tecartus) in the absence of unacceptable toxicity or development of ICANS. Patients who do not develop ICANS of any grade, also receive hydrocortisone IT on day 7 post SOC CAR T-cell therapy. Additionally, patients undergo cerebrospinal fluid (CSF) sample collection throughout the study.
After completion of study treatment, patients are followed for up to 30 days.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- OHSU Knight Cancer Institute
-
Hauptermittler:
- Stephen E. Spurgeon
-
Kontakt:
- Stephen E. Spurgeon
- Telefonnummer: 503-494-8950
- E-Mail: spurgeos@ohsu.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions
-
Age ≥ 18 years. All genders, races, and ethnic groups will be included
-
Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting
-
Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T
- Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
-
Platelet count > 50,000/mm^3 (μL)
-
Adequate coagulation tests including international normalized ratio (INR) < 1.6 and fibrinogen > 100
Exclusion Criteria:
-
Active/concurrent diagnosis of any central nervous system (CNS) hematologic malignancy
- History or presence of CNS disorder such as seizure disorder, transverse myelitis, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
-
Known history of hypersensitivity to IT chemotherapy
-
Subject has a contraindication to LP including:
- Presence of a posterior fossa mass
- Skin infection near puncture site
- Uncorrected bleeding diathesis
- Suspicion of increased intracranial pressure
- Acute spinal cord trauma
-
Subject is receiving an antiplatelet and/or anticoagulant that cannot be held prior to LP according to best available evidence
-
Known bleeding disorders
-
Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Supportive Care (cytarabine, methotrexate, hydrocortisone)
Patients receive cytarabine IT, methotrexate IT, and hydrocortisone IT over 3-5 minutes via LP on day 4 post-SOC CAR T-cell therapy in the absence of unacceptable toxicity or development of ICANS. Patients who do not develop ICANS of any grade, also receive hydrocortisone IT on day 7 post SOC CAR T-cell therapy. Additionally, patients undergo CSF sample collection throughout the study. |
Undergo lumbar puncture
Andere Namen:
Given IT
Andere Namen:
Given IT
Andere Namen:
Given IT
Andere Namen:
Undergo CSF sample collection
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of American Society for Transplantation and Cellular Therapy (ASTCT) ≥ grade 3 immune-effector cell associated neurotoxicity syndrome (ICANS)
Zeitfenster: From first dose of intrathecal (IT) chemotherapy (chimeric antigen receptor [CAR]-T day 4) to CAR-T day 30
|
Will be reported using the efficacy set. Point estimate, along with exact two-sided 95% confidence interval will be reported. |
From first dose of intrathecal (IT) chemotherapy (chimeric antigen receptor [CAR]-T day 4) to CAR-T day 30
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of ASTCT any grade ICANS
Zeitfenster: From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
Will be reported using the efficacy set. Point estimate, along with exact two-sided 95% confidence interval will be reported. |
From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
|
Incidence of lumbar puncture/IT treatment mediated adverse events (AEs) and serious adverse events (SAEs)
Zeitfenster: From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
Will be reported using the safety set. AEs will be tabulated by the Medical Dictionary for Regulatory Activities version (v) 21.1. preferred term and system organ class and a preferred term. The severity of the AE will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) v 5.0. Descriptive statistics using the safety evaluable population, will be used to report on all on-study AEs, grade 3-4 AEs, treatment-related AEs, grade 3-4 treatment-related AEs, SAEs, treatment-related SAEs, and AEs leading to discontinuation per CTCAE v 5.0. Grade 3-4 laboratory abnormalities will be summarized using worst grade NCI CTCAE v 5.0 criteria. |
From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
|
Mean (range) cumulative dose of corticosteroid use
Zeitfenster: From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
Will be reported using the efficacy set. The cumulative dose will be calculated as the sum of all corticosteroid administered over the study period, expressed in milligrams (mg) of prednisone-equivalent. |
From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
|
Incidence of anakinra use
Zeitfenster: From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
Will be reported using the efficacy set. Point estimate, along with exact two-sided 95% confidence interval will be reported. |
From first dose of IT chemotherapy (CAR-T day 4) to CAR-T day 30
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Stephen E Spurgeon, OHSU Knight Cancer Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Punktionen
- Chirurgische Eingriffe, operativ
- Nukleinsäuren, Nukleotide und Nukleoside
- Biopsie
- Polycyclische Verbindungen
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Nukleoside
- Pterins
- Pteridine
- Arabinonukleosides
- Aminopterin
- Schwangerschaften
- Schwanger
- 11-Hydroxycorticosteroide
- Hydroxykortikosteroide
- Nebennierenrindehormone
- 17-Hydroxycorticosteroide
- Diagnosetechniken, neurologisch
- Methotrexat
- Cytarabin
- Hydrocortison
- Handhabung von Proben
- Wirbelsäulenpunktion
- Merphos
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- STUDY00028106
- STUDY00028106 (Andere Kennung: OHSU Knight Cancer Institute)
- NCI-2025-00937 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .